Search Results - "Thamake, S"

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies by Chaudhary, P, Thamake, S I, Shetty, P, Vishwanatha, J K

“…Background: Annexin A2 (AnxA2), a calcium-dependent phospholipid binding protein, is abundantly present at the surface of triple-negative and…”
Get full text

An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma by Jonasch, E., Park, E., Thamake, S., Hirmand, M., Srinivasan, R.

Get full text

Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy by Thamake, S I, Raut, S L, Ranjan, A P, Gryczynski, Z, Vishwanatha, J K

“…This work reports the surface functionalization of polymeric PLGA nanoparticles by non-covalent insertion of a homo-bifunctional chemical crosslinker,…”
Get more information

921TiPAn open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma by Jonasch, E, Park, E, Thamake, S, Hirmand, M, Srinivasan, R

Get full text

PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1 by Sherif, B., Besse, B., Solomon, B., Bazhenova, L., Kim, D.W., Lin, J.J., Wolf, J., Popat, S., Goto, K., de Langen, A.J., Springfeld, C., Reynolds, M., Odom, D., Yuan, Y., Lee, A., Blum, S.I., Thamake, S., Ades, F., Drilon, A.

Get full text

1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial by Solomon, B.J., Drilon, A., Lin, J.J., Bazhenova, L., Goto, K., De Langen, J., Kim, D-W., Wolf, J., Springfeld, C., Popat, S., Lim, D.W-T., Baik, C.S., Hervieu, A., Moreno Garcia, V., Yang, N., Thamake, S., Ades, F., Trone, D., Besse, B.

Get full text

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) by Besse, B., Springfeld, C., Baik, C., Hervieu, A., Solomon, B., Moreno, V., Bazhenova, L., Goto, K., Kim, Y.C., Lu, S., Sun, M., Trone, D., Thamake, S., Cho, B.C., de Langen, A., Popat, S., Wolf, J., Moro-Sibilot, D., Fang, J., Drilon, A.

Get full text

911PD - A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E., Plimack, E.R., Bauer, T., Merchan, J.R., Papadopoulos, K.P., McDermott, D.F., Michaelson, M.D., Appleman, L.J., Thamake, S., Zojwalla, N., Choueiri, T.K.

“…Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a potent and selective…”
Get full text

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E., Plimack, E.R., Bauer, T., Merchan, J.R., Papadopoulos, K.P., McDermott, D.F., Michaelson, M.D., Appleman, L.J., Thamake, S., Zojwalla, N., Choueiri, T.K.

Get full text

LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease by Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W.K., Narayan, V.K., Maughan, B.L., Oudard, S., Else, T., Maranchie, J.K., Welsh, S.J., Thamake, S., Park, E.K., Perini, R.F., Linehan, W.M., Jonasch, E.

Get full text

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC by Jonasch, E, Plimack, E R, Bauer, T, Merchan, J R, Papadopoulos, K P, McDermott, D F, Michaelson, M D, Appleman, L J, Thamake, S, Zojwalla, N, Choueiri, T K

“…Abstract Background Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a…”
Get full text